BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 8402633)

  • 1. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
    Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
    Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
    Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
    Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
    den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
    Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
    Ward KW; Azzarano LM
    J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB; Duan J; Sridhar R; Damle BD
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
    Evers R; Kool M; Smith AJ; van Deemter L; de Haas M; Borst P
    Br J Cancer; 2000 Aug; 83(3):366-74. PubMed ID: 10917553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel multidrug resistance reversal agents.
    Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
    J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
    Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
    Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
    Dantzig AH; Shepard RL; Cao J; Law KL; Ehlhardt WJ; Baughman TM; Bumol TF; Starling JJ
    Cancer Res; 1996 Sep; 56(18):4171-9. PubMed ID: 8797588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.
    De Jong G; Gelmon K; Bally M; Goldie J; Mayer L
    Anticancer Res; 1995; 15(3):911-6. PubMed ID: 7645981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
    Bachmeier CJ; Trickler WJ; Miller DW
    Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.